Last reviewed · How we verify
Vonoprazan+amoxicillin+clarithromycin 7 days
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori eradication in peptic ulcer disease and gastritis.
At a glance
| Generic name | Vonoprazan+amoxicillin+clarithromycin 7 days |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall and ribosome (amoxicillin and clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the proton pump to reduce gastric acid, creating an optimal environment for antibiotic efficacy. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target bacterial cell wall synthesis and protein synthesis. Together, the reduced acid environment and dual antibiotic attack achieve high eradication rates of H. pylori infection.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease and gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication (PHASE3)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (PHASE4)
- Vonoprazan Hp Dual or Triple Eradication Regimes (PHASE4)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy (PHASE4)
- A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis (PHASE4)
- Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: